Search

300 Result(s)
Sort by

Embracing diversity in clinical trials

Embracing diversity in clinical trials

At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Rethinking mental health care

Rethinking mental health care

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Vaccine bluetongue virus serotype 3 sheep cattle

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Dedifferentiated liposarcoma (DDLPS)

Dedifferentiated liposarcoma (DDLPS)

An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Do we keep our promise?

Do we keep our promise?

Find out from a father-daughter duo how we live up to our new People Promise.
Results for Jardiance EMPACT-MI phase III trial

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Data Science

Data Science

Revolutionizing research and development with data driven insights
Supporting Fundappas

Supporting Fundappas

Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma